Prospective, Multi-Center, Observational, Program to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
Latest Information Update: 30 Oct 2019
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Spondylarthritis
- Focus Therapeutic Use
- Sponsors AbbVie
- 22 Oct 2019 Status changed from active, no longer recruiting to completed.
- 02 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2017 Status changed from not yet recruiting to recruiting.